Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives. Analysts have suggested that ...

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

Venezuela opposition leader Maria Corina Machado has been arrested, internet broadcaster VPI TV said on Thursday, citing ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

European markets are expected to open broadly lower Wednesday. The U.K.'s FTSE 100 index is expected to open 4 points lower ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...